Streptococcus Pneumoniae Serotype 14 Conjugate Vaccine
This is a monovalent pneumococcal conjugate vaccine that provides protection against Streptococcus pneumoniae serotype 14. It works by linking the capsular polysaccharide antigen to a diphtheria CRM197 carrier protein to enhance immune response, particularly in young children. This vaccine is used to prevent invasive pneumococcal diseases such as meningitis, bacteremia, and pneumonia caused by serotype 14.
A conjugate vaccine targeting Streptococcus pneumoniae serotype 14 to prevent invasive pneumococcal disease.
Key facts at a glance
- RxNorm
- 798220
- Generic
- Streptococcus Pneumoniae Serotype 14 Capsular Antigen Diphtheria Crm197 Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Prevnar 20, Vaxneuvance, Prevnar 13
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of invasive pneumococcal disease (including bacteremia, meningitis, and pneumonia) and otitis media caused by Streptococcus pneumoniae serotype 14. Similar to other pneumococcal conjugate vaccines, it may be used as part of pediatric immunization programs or in at-risk populations.
The vaccine contains the capsular polysaccharide from S. pneumoniae serotype 14, which is conjugated (chemically linked) to the CRM197 protein, a nontoxic mutant of diphtheria toxin. This conjugation converts the T-cell independent polysaccharide antigen into a T-cell dependent antigen, enhancing immunogenicity and enabling effective immune responses in young children who typically respond poorly to polysaccharide antigens alone.
Like all vaccines, contraindications include known hypersensitivity to any vaccine component. Adverse reactions may include injection site reactions, fever, and irritability. The CRM197 carrier protein may enhance immune response to co-administered vaccines. Efficacy depends on the individual's ability to mount an immune response. As with all pneumococcal vaccines, serotype 14 coverage may vary and does not protect against non-vaccine serotypes.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 30, 2026. · Read our editorial policy